lisdexamfetamine dimesylate
Making the shortlist for patient engagement and communications
Grace Communications has been shortlisted this year in both the PMi Awards and the Creative Floor Awards for an engaging creative campaign, putting patients at the forefront.
Mobilizing Agitation Detection in Children with ADHD
Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...
Healthware Group report on depression care in Italy highlights need for digital therapeutics
Mental health disorders are the fifth leading cause of disability adjusted life years in Italy
Mobilizing Agitation Detection in Children with ADHD
Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...
Mental Health Awareness Week
This year the theme of Mental Health Awareness Week is loneliness, focusing on the impact of it on our mental health and the practical steps we can take to address...
Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3
Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies
Supporting Mental Health During a Global Pandemic
Sam Duboc, Chair & CEO of MindBeacon, explores virtual care and telehealth for treating depression, anxiety, addiction, and other conditions; mental health issues brought on by COVID-19; and how to...
Biogen signs $3.1bn deal with Sage for potential depression therapies
Zuranolone already has a breakthrough therapy designation from the US FDA
Takeda to sell Japan consumer health unit for $2.3bn
Deal helps to reduce debt accrued from Shire takeover
Acadia’s Nuplazid misses the mark in major depressive disorder trial
Company's efforts to extend drug's reach fall flat
Impetus Digital Fireside Chat with with Jon Sockell, Co-Founder/COO of Limbix
Jon Sockell, Co-founder and COO of Limbix, sits down with us in this Fireside Chat. See how Limbix is paving the way for prescription digital therapeutics and learn from their trials,...
